A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

Summary

The purpose of this Phase 1 study is to evaluate the safety and tolerability of CC-96673 in adult participants with Relapsed or Refractory Non-Hodgkin's Lymphoma (R/R NHL). The study will be conducted in 2 parts: Part A, monotherapy dose escalation and Part B, monotherapy dose expansion.

Timeline

Start

2022-01-20

Primary completion

2024-07-31

Completion

2024-07-31

Outcome

Outcome not reported

Stopped (Business): “Business objectives have changed.”

Drugs

Indications